Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | 500,000 |
| Gross Profit (TTM) | 367,000 |
| EBITDA | $-35.58M |
| Operating Margin | -7242.00% |
| Return on Equity | -75.90% |
| Return on Assets | -41.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.26 |
| Price-to-Book | 0.97 |
| Price-to-Sales (TTM) | 78.53 |
| EV/Revenue | 5.86 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $159.62M |
| Float | $572.33M |
| % Insiders | 0.96% |
| % Institutions | 42.43% |
Volatility is currently expanding